4 March 2015
Update | Sector: Healthcare
Sun Pharma
BSE Sensex
29,381
S&P CNX
8,923
CMP: INR1,005
TP: INR1,220 (+21%)
Buy
Halol concerns allayed – reiterate as top pick
Ranbaxy merger completion imminent, synergies to unlock value
Stock Info
Bloomberg
Equity Shares (m)
M.Cap.(INR b)/(USD b)
52-Week Range (INR)
1, 6, 12 Rel. Per (%)
Avg Val(INRm)/Vol‘000
Free float (%)
SUNP IN
2,071.1
2083/33.4
1,035/553
9/10/23
1875/2558
36.4
Sun Pharma Advanced Research Company (SPARC) announced USFDA approval
for its NDA Elepsia XR, which was filed from Sun Pharma’s (SUNP) Halol facility
(largest facility for the US). This is the first product approval since Form 483
issuance (23 observations, Sep’14) at Halol, implying likely clearance of the
facility by USFDA. This removes a key overhang on SUNP, as a timely closure of
USFDA issues reflects SUNP’s strong focus on quality/compliance and paves way
for new product approvals, key for SUNP’s growth in the US (60% of total sales).
US pipeline focused on differentiation, await pickup in new approvals:
SUNP’s focus on complex generics in the US is likely to bear fruit over the next
few years, with 228 pending ANDAs (including 30 in Taro). With only 15 ANDA
approvals (inc. 4 for Taro) YTD in the US, growth for FY15 has been impacted.
However, we expect bunched-up product approvals by USFDA, as GDUFA
implementation gathers pace. Halol accounted for 25%+ of US sales and hence
clearance of the same is critical for upcoming launches’ visibility. We expect
SUNP’s US business to post 18% CAGR over FY15E-17E, with key launches like
gActonel, gFocalin, gGleevec having the potential to surprise positively.
Financial Snapshot (INR Billion)
Y/E Mar
2015E 2016E 2017E
Sales
180.4 212.4 252.7
EBITDA
Rep. PAT
Rep.EPS (INR)
EPS Gr. (%)
BV/Sh. (INR)
RoE (%)
RoCE (%)
Payout (%)
Valuations
P/E (x)
P/BV (x)
EV/EBITDA (x)
Div. Yield (%)
31.7
8.7
22.9
0.4
27.9
6.9
19.4
0.5
22.2
5.4
15.4
0.6
85.0
65.7
31.7
109.0
30.8
37.1
13.8
97.5 118.2
74.6
36.0
13.6
27.5
36.1
14.6
93.7
45.2
25.5
27.3
35.4
14.2
116.2 146.4 184.6
Strengthening backward linkage for controlled substance:
Recent
acquisition of GSK’s Opiates business in Australia solidifies SUNP’s presence in
controlled substances globally (USD10b+ market). The acquired operations
reported revenue of ~USD65m with marginal profitability but supplies 25% of
the world’s medicinal opiate needs. Hence, it is a strategic asset as SUNP looks
to intensify focus on low competition segments and has forward linkages
through Hungary (ICN) and New Jersey (Able Labs) in the controlled substance.
Synergy target from RBXY achievable:
With only the Punjab and Haryana
High Court approval pending, we expect merger with RBXY to be completed by
March 2015. We believe SUNP’s target of USD250m synergy benefit is realistic,
noting largely non-overlapping businesses and SUNP’s sharp focus on cost
containment to drive margin expansion for Ranbaxy (from 15% now to 20% by
FY17E). We expect the RBXY deal to be EPS accretive from FY17 itself.
Merits premium multiples, remains our top pick:
We believe SUNP would
continue to trade at premium valuations due to superior execution track
record, high RoIC (46% versus 35% for peers) and potential for accretive M&A
(USD2b cash). We estimate an EPS CAGR of 19% over FY15E-17E, despite surge
in R&D spend (novel molecule) restraining margins. We raise our target price
to INR1,220 (27x FY17E) mainly on inclusion of gGleevec in our estimates
(RBXY not included in our assumptions).
Risks:
execution challenges on RBXY
integration, resolution of USFDA issues at RBXY facilities, currency fluctuation.
Arvind Bothra(Arvind.Bothra@MotilalOswal.com);+91
22 3982 5584
Amey Chalke(Amey.Chalke@MotilalOswal.com);+91
22 3982 5423
Investors are advised to refer through disclosures made at the end of the Research Report.
Motilal Oswal research is available on
www.motilaloswal.com/Institutional-Equities,
Bloomberg, Thomson Reuters, Factset and S&P Capital.

Sun Pharma
RBXY merger to be accretive from FY17 itself
Exhibit 1: Proforma income statement for the combined entity
Sun Pharma
Particulars (INR m)
Sales
EBITDA
EBITDA margin
Depreciation
Interest Expense
Other Income
Exceptionals
PBT
Tax
PAT
Adjustment
Minority Interest
Reported PAT
No of shares
EPS, INR
FY15
180,447
85,050
47.1%
5,604
733
4,208
0
82,921
8,519
74,401
0
8,718
65,684
2071.2
31.7
FY16
212,434
97,501
45.9%
6,822
697
7,629
0
97,611
14,642
82,969
0
8,331
74,639
2071.2
36.0
FY17
252,698
118,217
46.8%
7,186
662
10,510
0
120,880
18,132
102,748
0
9,044
93,704
2071.2
45.2
FY15
107,997
16,582
15.4%
4,111
2,908
685
6,288
3,960
1,813
2,147
0
129
2,018
423.32
4.8
Ranbaxy
FY16
117,923
19,567
16.6%
5,102
2,354
1,420
0
13,531
3,518
10,013
0
250
9,763
423.32
23.1
21,602
5,616
15,985
0
293
15,692
423.32
37.1
67,702
2409.8
28.1
84,402
2409.8
109,396
2409.8
FY17
141,611
27,923
19.7%
5,529
2,354
1,562
FY15
288,444
101,631
35.2%
9,715
3,641
4,893
6,288
86,880
10,332
76,549
0
Combined
FY16
330,357
117,068
35.4%
11,925
3,051
9,049
0
111,142
18,160
92,982
0
FY17
394,309
146,141
37.1%
12,715
3,016
12,072
0
142,482
23,749
118,734
0
35.0
45.4
Source: Company, MOSL
Exhibit 2: Expects deal closure by March 2015
Event
Announces merger with Ranbaxy (valuing at USD 4b)
Approvals from stock exchanges (both NSE and BSE)
CCI asks to publish details of the merger
High court approvals ( Gujarat, Punjab and Haryana)
FIPB approval
Competition Commission of India approval
US Federal Trade Commission
Punjab and Haryana High Court approval
Timeline
7/4/2014
22/7/2014
28/8/2014
24/11/2014
1/12/2014
8/12/2014
2/2/2015
Awaited
Received
Submitted
Gujarat high court approval received
Received, for issuance of shares to Daiichi Sankyo
Received, subject to divestiture of 7 brands
Received, subject to divestment of Ranbaxy's
interests in generic Minocycline (deal with Torrent
Pharma)
Likely by March 2015 end.
Source: Company, MOSL
Status
4 March 2015
2

Sun Pharma
Strong US pipeline focused on complex generics
Exhibit 3: Anticipated key launches in the US
Brand
Nexium IV
Zemplar
Yaz
Hectorol-Inj
Lexapro
Nexium
Pristiq
Actonel
Focalin
Namenda
Abilify
Gleevec
Coreg CR
Focalin
Ortho Tri Cyclen Lo
Crestor
Glumetza
Multaq
Azilect
Strattera
Treximet
Lyrica
Vimpat
Janumet
Januvia
Angiomax
Alimta
Asacol / Lialda
Effient
Kombiglyze XR
Naftin
Nasonex / Asmanex / Elocon
Onglyza
Prevacid
Renagel/Renvela
Toviaz
Treanda
Uloric
Product
Esomeprazole-IV
paricalcitol
Drospirenone
Doxercalciferol
Escitalopram Oxalate
Esomeprazole-Tabs
Desvenlafaxine
Risedronate
Dexmethylpenidate
Memantine
Aripiprazole- Oral
Imatinib
Carvedilol
Dexmethylphenidate Hcl
Ethinyl Estradiol; Norgestimate
Rosuvastatin
Metformin HCL ER tabs
Dronedarone
Rasagiline Mesylate
Atomoxetine
Naproxen Sodium; Sumatriptan Succinate
Pregabalin
Lacosamide
Sitagliptin+Metformin
Sitagliptin
Bivalirudin
Pemetrexed Disodium
Mesalamine
Prasugrel
Saxagliptin+metformin
Naftifine
Mometasone Furoate
Saxagliptin
Lansoprazole
Sevelamer Carbonate
Fesoterodine Fumarate
Bendamustine
Febuxostat
Brand sales (USD m)
20
310
85
207
2,259
6,000
500
800
500
1,700
5,674
1,800
211
500
410
4,953
123
300
1,000
556
105
1,952
353
500
1,700
444
1,100
1,000
377
165
100
1,230
426
250
700
130
531
220
Timeline
Delayed
Delayed
Delayed
Delayed
Delayed
FY16
FY16
FY16
FY16
FY16
FY16
FY16
FY16
FY16
FY16
FY17
FY17
FY17
FY17
FY18
FY18
FY19
FY23
FY23
FY23
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Source: US FDA, MOSL
4 March 2015
3

Sun Pharma
Diversified manufacturing base for US
Exhibit 4: Details of SUNP’s manufacturing facilities for the US market
Facility
Halol, India
Bryan, Ohio, USA
Detroit, USA
Cranbury, NJ
Dadra Nagar Haveli
Panoli, Gujarat
Ahmednagar
Chattanooga, USA
Hungary
Karkhadi
Philadelphia, PA -2
Philadelphia, PA - 1
Aurora, IL
Taro Facilities
Canada
Israel
Hawthorne, NY
Formulations
API + Formulations
Formulations
Feb-14
Dec-12
Apr-13
Y
N
Y
Source: Company, MOSL
Form
Formulations
Formulations
Formulations
Formulations
Formulations
API
API
API
API + Formulations
API + Formulations
Formulations
Formulations
Last inspection
Sep-14
Jun-13
May-13
May-13
May-13
Jun-12
Sep-12
Jul-13
NA
Nov-13
Sep-12
Jul-14
Feb-13
483 issue
Y
Y
N
Y
N
Y
Y
N
NA
Y
N
Y
N
Remarks
Received 483 in Sep-14. Received
NDA approval in Mar’15 (Elepsia
XR) for SPARC’s filing.
Able Labs facility
Caraco facility. Sun has decided to
shut down in Jun'14
Controlled substance (Able Labs)
NA
Key API plants for peptides, anti-
cancer, steroids, sex hormones
Key API plants for controlled
substances.
Under import alert. Small
contribution to current operations
(cephalosporin products)
URL facility
URL facility
URL facility
Had received warning letter in
Feb-09. Resolved in Apr-11.
Taro Facility
SUNP to benefit from limited competition in gGleevec
Exhibit 5: gGleevec opportunity assumptions
Annual brand sales (USD m)
1,800
180 days exclusivity
FY16E
FY17E
Price erosion
60%
60%
Residual market (USD m)
120
240
SUNP share (%)
30%
40%
SUNP sales (USD m)
36
96
PAT %
60%
60%
SUNP PAT (USD m)
21.6
57.6
USD/ INR rate
62.0
62.0
SUNP sales (INR m)
2,232
5,952
SUNP PAT (INR m)
1,339
3,571
SUNP EPS (INR/share)
0.6
1.7
Post exclusivity
FY17E
70%
360
40%
144
60%
86.4
62.0
8,928
5,357
2.6
Source: Company, MOSL
4 March 2015
4

Sun Pharma
Valuation and view
SUNP has historically commanded 20-25% premium to Indian pharma peers,
typically at 25-27x one-year forward P/E multiples. The stock trades at 27.5x FY16E
and 22.2x FY17E, which does not fully value its rich US pipeline and stable, cash
generating domestic business. Consistent outperformance in the domestic market,
with market share gains and high profitability reflect management’s execution
capability (and product selection skills). Identification of value-accretive assets and
integrating them successfully has been one of the cornerstones of SUNP’s success.
We believe the valuation premium is likely to be maintained due to:
n
High earnings visibility on an elevated base
(forecast EPS CAGR of 19% over
FY15E-17E).
n
Sustained improvement in RoIC, implying high capital efficiency.
We expect
RoIC to expand from 46.1% in FY15E to 51% by FY17E (v/s 35% average for large
caps).
n
Strong cash generation and healthy balance sheet.
We expect SUNP to
generate INR221b free cash flows over FY15E-17E and its cash surplus to reach
INR234b (56%+ of capital employed) and,
n
Impeccable execution track record.
SUNP has consistently beaten its own
guidance and consensus estimates over the last five years by a margin. Greater
focus on capital efficiency and profitability (over size) has catapulted SUNP to
the current level.
Our target price implies 21% upside
We raise the target price to factor inclusion of gGleevec in our assumptions. With
Halol facility cleared by USFDA, visibility on new launches improves further. We
assign a target P/E of 27x to SUNP’s FY17E EPS of INR45.2 and arrive at a target price
of INR1,220, implying 21% upside from current levels. Our target multiple is:
n
At the higher end of its historic average P/E band (one-year forward).
n
At 30% premium to sector average P/E of 21x, in line with the past average.
n
In line with the current trading multiple (FY16E P/E).
Key catalysts going forward are:
n
n
n
We have not factored any potential acquisition that SUNP may enter (net cash
surplus) as well as positive development of its novel molecule (tildrakizumab, in-
licensed from Merck).
RBXY’s financials are not factored in our estimates, pending the deal closure.
However, our proforma analysis suggests the deal to be EPS accretive by FY17.
Execution of RBXY’s integration would be a key catalyst to watch for.
Higher-than-expected upsides from niche molecules in the US (Gleevec).
Risks to our assumptions are:
n
Currency volatility:
SUNP derives more than 73% of its revenue (and profits)
from overseas business (largely the US) and hence is affected by currency
fluctuations on an operational level. As a prudent measure though, company
hedges ~50% of its net exposure to USD through forward covers (<12-month
5
4 March 2015

Sun Pharma
n
duration). A reversal in the current trend (INR appreciation) thus poses a
downside risk to estimates.
Increased competition in US derma market:
Taro accounts for 26% of SUNP’s
business and is currently benefiting from a lack of competition in the US derma
market (and price hikes). We do not expect a new player’s entry for four to five
years at least due to development timeline etc. However, if some of the
approved players (two to three) re-enter the market, there could be a risk to
pricing in the US derma market, thus affecting SUNP (Taro) adversely.
Exhibit 7: SUNP deserves premium to Sector PE (x)
3 Yrs Avg(x)
10 Yrs Avg(x)
27.9
35
Healthcare Sector PE (x)
LPA (x)
26.8
25
Exhibit 6: One-year forward PE band (x)
40
30
20
18.6
10
0
P/E (x)
5 Yrs Avg(x)
23.5
21.3
15
20.5
5
Source: Company, MOSL
Source: Company, MOSL
Financials and valuations
Key Assumptions
Revenue Growth (%)
India
USA
Taro
Ex-Taro
SUN-US
URL
DUSA
RoW
API
Total sales
Expenses
Raw material
Staff cost
R&D cost
EBITDA Margins
2010
-6.6
-28.2
0.0
-28.2
-28.2
0.0
0.0
27.1
13.3
-6.8
27.4
10.0
5.2
34.0
2011
30.1
102.7
0.0
33.5
33.5
0.0
0.0
34.1
-5.1
42.5
24.0
12.1
5.0
34.3
2012
22.5
54.0
206.0
-24.8
-24.8
0.0
0.0
72.6
17.9
39.8
19.2
12.6
4.9
40.0
2013
1.7
77.3
30.8
175.3
152.0
0.0
0.0
37.3
22.8
40.5
18.4
13.6
5.5
44.0
2014
24.5
59.0
34.4
83.6
23.0
881.7
427.0
25.0
6.1
42.0
17.3
12.9
6.5
43.5
2015E
19.7
13.0
17.6
9.6
21.4
-21.6
42.5
5.2
-2.6
12.8
17.2
12.8
6.5
47.3
2016E
19.0
17.1
16.4
17.6
16.5
16.6
26.9
23.6
6.6
17.7
2017E
19.5
19.0
15.0
22.1
23.0
18.0
25.0
22.4
5.0
19.0
17.7
18.0
12.6
12.2
7.5
8.0
46.1
47.0
Source: Company, MOSL
4 March 2015
6

Sun Pharma
Financials and valuations
Income Statement
(Consolidated)
Y/E March
Net Sales
Change (%)
Total Expenditure
% of Sales
EBITDA
Margin (%)
Depreciation
EBIT
Int. and Finance Charges
Other Income - Rec.
Extra-ordinary Exp
PBT
Tax
Tax Rate (%)
Profit after Tax
Change (%)
Margin (%)
Less: Mionrity Interest
Reported PAT
2010
40,075
-6.2
26,441
66.0
13,633
34.0
1,533
12,100
0
2,048
0
14,148
679
4.8
13,470
-28.3
34
-41
13,511
2011
57,214
42.8
37,648
65.8
19,566
34.2
2,049
17,518
739
3,611
32
20,357
1,286
6.3
19,072
41.6
33
913
18,158
2012
80,098
40.0
48,152
60.1
31,947
39.9
2,912
29,035
282
4,856
11
33,598
3,826
11.4
29,772
56.1
37
3855
25,917
2013
112,388
40.3
63,326
56.3
49,063
43.7
3,362
45,701
443
3,727
5,836
43,148
8,456
19.6
34,693
16.5
31
4863
29,830
2014
160,044
42.4
90,787
56.7
69,257
43.3
4,092
65,165
442
6,282
25,174
45,831
7,022
15.3
38,809
11.9
24
7375
31,434
2015E
180,447
12.7
95,397
52.9
85,050
47.1
5,604
79,446
733
4,208
0
82,921
8,519
10.3
74,401
91.7
41
8718
65,684
2016E
212,434
17.7
114,933
54.1
97,501
45.9
6,822
90,678
697
7,629
0
97,611
14,642
15.0
82,969
11.5
39
8331
74,639
(INR Million)
2017E
252,698
19.0
134,481
53.2
118,217
46.8
7,186
111,032
662
10,510
0
120,880
18,132
15.0
102,748
23.8
41
9044
93,704
Balance Sheet
(Consolidated)
Y/E March
Equity Share Capital
Total Reserves
Net Worth
Minority Interest
Deferred Liabilities
Total Loans
Capital Employed
Gross Block
Less: Accum. Deprn.
Net Fixed Assets
Capital WIP
Goodwill
Investments
Curr. Assets
Inventory
Account Receivables
Cash and Bank Balance
L & A and Others
Curr. Liability & Prov.
Account Payables
Provisions
Net Current Assets
Appl. of Funds
E: MOSL Estimates
2010
1,036
77,254
78,289
1,932
-890
1,712
81,042
20,880
7,239
13,642
1,448
5,747
31,664
36,121
10,739
11,748
5,089
8,546
7,579
4,095
3,484
28,542
81,042
2011
1,036
93,798
94,833
8,472
-3652
3,717
103,370
39,128
16,794
22,334
2,355
10,599
22,297
61,146
14,895
11,049
22,046
13,156
15,361
10,078
5,283
45,785
103,371
2012
1,036
120,628
121,663
11,616
-5199
2,739
130,820
46,542
20,406
26,136
3,447
13,378
22,129
90,681
20,870
19,261
33,672
16,878
24,950
14,410
10,541
65,730
130,820
2013
1,036
148,862
149,897
16,351
-7122
2,072
161,197
56,026
24,421
31,604
5,626
24,870
24,116
113,420
25,778
27,108
40,587
19,948
38,439
15,752
22,687
74,981
161,198
2014
2,071
183,178
185,249
19,212
-9110
24,982
220,333
63,886
28,904
34,982
8,415
33,191
27,860
177,393
31,230
22,004
75,902
48,257
61,509
15,887
45,622
115,884
220,333
2015E
2,071
238,563
240,634
27,930
-9110
403
259,857
72,886
34,508
38,378
8,415
33,191
27,860
223,121
33,252
30,596
105,086
54,188
71,109
20,586
50,523
152,012
259,857
2016E
2,071
301,085
303,157
36,260
-9110
403
330,710
81,886
41,330
40,555
8,415
33,191
27,860
298,551
40,236
36,037
161,400
60,878
77,863
24,910
52,953
220,688
330,710
(INR Million)
2017E
2,071
380,250
382,321
45,305
-9110
403
418,919
90,886
48,516
42,370
8,415
33,191
27,860
391,250
45,942
42,841
234,039
68,427
84,168
28,443
55,725
307,082
418,918
4 March 2015
7

Sun Pharma
Financials and valuations
Ratios
Y/E March
EPS
Fully Diluted EPS
Cash EPS
BV/Share
DPS
Payout (%)
Valuation (x)
P/E
P/BV
EV/Sales
EV/EBITDA
Dividend Yield (%)
Return Ratios (%)
RoE
RoCE
Working Capital Ratios
Fixed Asset Turnover (x)
Debtor (Days)
Inventory (Days)
Working Capital T/O (Days)
Leverage Ratio
Interest Cover Ratio
Debt/Equity (x)
2010
6.5
6.5
7.3
37.8
1.4
24.7
154.1
26.6
51.1
150.1
0.1
18.2
18.6
3.0
107
98
214
-
0.0
21.0
23.6
3.2
70
95
151
23.7
0.0
23.9
30.4
3.3
88
95
146
103.0
0.0
2011
8.8
8.8
9.8
45.8
1.7
22.1
2012
12.5
12.5
13.9
58.7
2.1
17.2
2013
14.4
14.4
16.0
72.4
2.5
17.5
69.8
13.9
18.0
41.1
0.2
22.0
31.5
3.9
88
84
112
103.1
0.0
2014
15.2
15.2
17.2
89.4
3.0
18.7
66.2
11.2
12.5
28.9
0.3
18.8
25.6
4.8
50
71
91
147.5
0.2
2015E
31.7
31.7
34.4
116.2
4.3
13.8
31.7
8.7
10.8
22.9
0.4
30.8
37.1
4.9
62
67
95
108.3
0.0
2016E
36.0
36.0
39.3
146.4
5.0
14.6
27.9
6.9
8.9
19.4
0.5
27.5
36.1
5.4
62
69
102
130.2
0.0
2017E
45.2
45.2
48.7
184.6
6.0
14.2
22.2
5.4
7.2
15.4
0.6
27.3
35.4
6.1
62
66
106
167.8
0.0
Cash Flow Statement
(Consolidated)
Y/E March
OP/(Loss) bef. Tax
Int./Dividends Recd.
Direct Taxes Paid
(Inc)/Dec in WC
CF from Operations
(inc)/dec in FA
(Pur)/Sale of Invest.
CF from investments
Change in networth
(Inc)/Dec in Debt
Interest Paid
Dividend Paid
CF from Fin. Activity
Inc/Dec of Cash
Add: Beginning Balance
Closing Balance
2010
13,633
2,048
-890
-4,659
10,133
-2,920
-13,069
-15,988
-2,347
-77
0
-3,321
-5,746
-11,601
16,690
5,089
2011
19,534
3,611
-4,048
-286
18,811
-16,500
9,367
-7,134
8,225
2,006
-739
-4,213
5,280
16,957
5,089
22,046
2012
31,935
4,856
-5,373
-8,319
23,099
-10,585
169
-10,416
5,318
-978
-282
-5,115
-1,058
11,626
22,046
33,672
2013
43,227
3,727
-10,379
-2,336
34,239
-22,501
-1,987
-24,488
4,334
-668
-443
-6,058
-2,835
6,915
33,672
40,587
2014
44,083
6,282
-9,010
-5,589
35,767
-18,580
-3,745
-22,324
6,674
22,910
-442
-7,270
21,872
35,315
40,587
75,902
2015E
85,050
4,208
-8,519
-6,943
73,796
-9,000
0
-9,000
0
-24,578
-733
-10,299
-35,610
29,185
75,902
105,087
2016E
97,501
7,629
-14,642
-12,361
78,127
-9,000
0
-9,000
0
0
-697
-12,116
-12,813
56,314
105,086
161,400
(INR Million)
2017E
118,217
10,510
-18,132
-13,755
96,841
-9,000
0
-9,000
0
0
-662
-14,540
-15,201
72,639
161,400
234,039
4 March 2015
8

Sun Pharma
Corporate profile: Sun Pharma
Company description
Sun Pharma is among the largest players in the
domestic formulations market and the most
profitable one. It makes and markets specialty
medicines and APIs for chronic therapy areas such
as cardiology, psychiatry, neurology, etc. Sun has
forayed into regulated markets by acquiring
majority stake in Caraco Pharma and has
strengthened its presence in US by recent
acquisition of Taro.
Exhibit 8: Sensex rebased
Exhibit 9: Shareholding pattern (%)
Dec-14
Promoter
DII
FII
Others
63.7
4.9
21.7
9.8
Sep-14
63.7
4.6
22.8
9.0
Dec-13
63.7
5.7
22.5
8.1
Exhibit 10: Top holders
Holder Name
Genesis Indian Investment Company Ltd General Sub
Lakshdeep Investments & Finance Pvt Ltd
LIC of India Profit Plus Balanced Fund
Abu Dhabi Investment Authority-Baihu
% Holding
2.3
1.6
1.4
1.2
Note: FII Includes depository receipts
Exhibit 11: Top management
Name
Israel Makov
Dilip S Shanghvi
Designation
Chairman
Managing Director
Exhibit 12: Directors
Name
Israel Makov
Dilip S Shanghvi
Ashwin Dani*
Keki M Mistry*
Hasmukh S Shah*
*Independent
Name
S Mohanchand Dadha*
Sudhir V Valia
Sailesh T Desai
Rekha Sethi*
Exhibit 13: Auditors
Name
Deloitte Haskins & Sells LLP
Kailash Sankhlecha & Associates
Type
Statutory
Cost Auditor
Exhibit 14: MOSL forecast v/s consensus
EPS
(INR)
FY15
FY16
FY17
MOSL
forecast
31.7
36.0
45.2
Consensus
forecast
29.8
35.4
42.0
Variation
(%)
6.2
1.6
7.6
4 March 2015
9

Sun Pharma
This document has been prepared by Motilal Oswal Securities Limited (hereinafter referred to as Most) to provide information about the company(ies) and/sector(s), if any, covered in the report and may be
distributed by it and/or its affiliated company(ies). This report is for personal information of the selected recipient/s and does not construe to be any investment, legal or taxation advice to you. This research report does
not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not
for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal
recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider
whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as
up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur.
MOSt and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a
some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that MOSt and/or
its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this
material may educate investors on investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other
parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on the profitability of MOSt which may include earnings from investment banking and other business.
MOSt generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
Additionally, MOSt generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders,
and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary
trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing
among other things, may give rise to real or potential conflicts of interest. MOSt and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position
in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation
or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with
respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations
made by the analyst(s) are completely independent of the views of the affiliates of MOSt even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report
Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as
such, may not match with a report on a company's fundamental analysis. In addition MOST has different business segments / Divisions with independent research separated by Chinese walls catering to different set
of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets.
Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOSt or any of its affiliates or
employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSt or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSt or any of
its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is
based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOSt’s interpretation of the data, information and/or opinions
provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or
summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOSt and/or its affiliates are under no obligation to
update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOSt and/or its affiliates from doing so. MOSt or any of its affiliates or employees shall not be in any way
responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time,
any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations.
This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on
this report or for any necessary explanation of its contents.
Most and it’s associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any
compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.
Most and it’s associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
Subject Company may have been a client of Most or its associates during twelve months preceding the date of distribution of the research report
MOSt and/or its affiliates and/or employees may have interests/positions, financial or otherwise of over 1 % at the end of the month immediately preceding the date of publication of the research in the securities
mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the
report.
Motilal Oswal Securities Limited is under the process of seeking registration under SEBI (Research Analyst) Regulations, 2014.
There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities
Analyst Certification
The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be
directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation
of MOSt research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues
Disclosure of Interest Statement
§
Analyst ownership of the stock
§
Served as an officer, director or employee
SUN PHARMA
No
No
Disclosures
Regional Disclosures (outside India)
For U.S.
This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law,
regulation or which would subject MOSt & its group companies to registration or licensing requirements within such jurisdictions.
Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In
addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the
United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or
intended for U.S. persons.
This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional
investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major
institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the
"Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning
agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this
chaperoning agreement.
The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL,
and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.
For Singapore
Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors
Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to
accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time.
In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited:
Anosh Koppikar
Kadambari Balachandran
Email : anosh.Koppikar@motilaloswal.com
Email : kadambari.balachandran@motilaloswal.com
Contact : (+65)68189232
Contact : (+65) 68189233 / 65249115
Office Address : 21 (Suite 31),16 Collyer Quay,Singapore 04931
Motilal Oswal Securities Ltd
4 March 2015
Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025
Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com
10